Journal of Pharmaceutical Health Care and Sciences, 2021 Background Patients with chronic heart failure (CHF) are often treated using many diuretics for symptom relief; however, diuretic use may have to continue despite hypotension development in these patients.
Yuki Asai +6 more
semanticscholar +3 more sources
Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
International Journal of General Medicine, 2021 Droxidopa is approved for the treatment of neurogenic orthostatic hypotension (nOH) symptoms and requires patients to be titrated to individualized effective doses (100–600 mg, three times daily) based on symptomatic response.
Fahd Amjad, Brett Polenchar, A. Favit
semanticscholar +3 more sources
Characterization of the changes in supine blood pressure with
Health Science Reports, 2021 Background and Aims Patients with neurogenic orthostatic hypotension (nOH) due to autonomic dysfunction may also experience supine hypertension (defined as supine systolic blood pressure [SBP] ≥140 mmHg).
L. Arthur Hewitt +5 more
openalex +2 more sources
Computational analysis of RNA methyltransferase Rv3366 as a potential drug target for combating drug-resistant Mycobacterium tuberculosis. [PDF]
Front Mol Biosci, 2023 Mycobacterium tuberculosis (M.tb) remains a formidable global health threat. The increasing drug resistance among M.tb clinical isolates is exacerbating the current tuberculosis (TB) burden.
Nazim T +6 more
europepmc +2 more sources
2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension [PDF]
Journal of Clinical and Translational Science, 2018 OBJECTIVES/SPECIFIC AIMS: To describe adverse behavioral symptoms attributed to droxidopa therapy for neurogenic orthostatic hypotension (nOH). METHODS/STUDY POPULATION: BACKGROUND: Droxidopa, a norepinephrine (NE) precursor, improves symptoms of nOH by ...
Katherine E. McDonell +4 more
openalex +3 more sources
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension [PDF]
BMC Neurology, 2017 Background Droxidopa, a prodrug of norepinephrine, was approved for treatment of neurogenic orthostatic hypotension (nOH) due to primary autonomic disorders based on 3 randomized double-blind studies.
Italo Biaggioni +3 more
openalex +3 more sources
POS-800 DROXIDOPA FOR MANAGEMENT OF CHRONIC HYPOTENSION IN HAEMODIALYSIS
Kidney International Reports, 2021 Anuradha Jayanti +4 more
openalex +3 more sources
Sleep Architecture Alterations Following High-Dose Steroid Pulse Therapy: A Pilot Study Using a Portable Electroencephalogram-Based Device. [PDF]
Neuropsychopharmacol RepHigh‐dose steroid pulse therapy markedly reduces total sleep time, REM, and NREM sleep, as objectively demonstrated for the first time using a portable EEG‐based device. ABSTRACT Background Sleep disturbance is a common side effect of high‐dose steroid pulse therapy (SPT).
Endo H +12 more
europepmc +2 more sources
Droxidopa for refractory neurogenic orthostatic hypotension in amyloid light chain amyloidosis
American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2023 Neurogenic orthostatic hypotension (nOH) secondary to amyloidosis is a rare condition associated with significant blood pressure (BP) drops and problematic symptoms for patients.
Hien Ha, N. L. Nguyen
semanticscholar +1 more source
Characteristics, Management, and Outcomes of Hospitalized Patients with Orthostatic Hypotension. [PDF]
J Clin Hypertens (Greenwich)ABSTRACT Orthostatic hypotension (OH) is a common inpatient condition associated with falls, syncope, and mortality. However, standardized approaches for inpatient management of OH are lacking and may vary across clinical specialties. In this retrospective observational cohort study, we reviewed the electronic medical records of patients admitted to ...
Wagner BA +5 more
europepmc +2 more sources